Development of a next generation risk assessment framework for the evaluation of skin sensitisation of cosmetic ingredients

• Published in: Regulatory toxicology and pharmacology 2020-10, Vol.116, p.104721, Article 104721
• Main Authors: Gilmour, Nicola, Kern, Petra S., Alépée, Nathalie, Boislève, Fanny, Bury, Dagmar, Clouet, Elodie, Hirota, Morihiko, Hoffmann, Sebastian, Kühnl, Jochen, Lalko, Jon F., Mewes, Karsten, Miyazawa, Masaaki, Nishida, Hayato, Osmani, Anne, Petersohn, Dirk, Sekine, Shuichi, van Vliet, Erwin, Klaric, Martina
• Format: Article
• Language: English
• Subjects: Allergens - toxicity; Animal Testing Alternatives; Animals; Computer Simulation; Cosmetics - toxicity; Haptens - toxicity; Humans; Risk Assessment - methods; Skin - drug effects
• ISSN: 0273-2300; 1096-0295
• DOI: 10.1016/j.yrtph.2020.104721

All cosmetic products placed onto the market must undergo a risk assessment for human health to ensure they are safe for consumers, including an assessment of skin sensitisation risk. Historically, in vivo animal test methods were used to identify and characterise skin sensitisation hazard, however non-animal and other new approach methodologies (NAMs) are now the preferred and mandated choice for use in risk assessment for cosmetic ingredients. The experience gained over the last three decades on how to conduct risk assessments based upon NAMs has allowed us to develop a non-animal, next generation risk assessment (NGRA) framework for the assessment of skin sensitisers. The framework presented here is based upon the principles published by the International Cooperation on Cosmetic Regulation (ICCR) and is human relevant, exposure led, hypothesis driven and designed to prevent harm. It is structured in three tiers and integrates all relevant information using a weight of evidence (WoE) approach that can be iterated when new information becomes available. The initial tier (TIER 0) involves a thorough review of the existing information including; identification of the use scenario/consumer exposure; characterisation of the chemical purity and structure; in silico predictions; existing data pertaining to skin sensitisation hazard (historical or non-animal); the identification of suitable read-across candidates with supporting hazard identification/characterisation information and application of exposure-based waiving. Considering all information identified in TIER 0, the next step is the generation of a hypothesis (TIER 1). All data are considered in an exposure-led WoE approach, taking into account an initial view on whether a chemical is likely to be a skin sensitiser or not, choice of defined approach (DA) and availability of read-across candidates. If existing information is insufficient for concluding the risk assessment, the generation of additional information may be required to proceed (TIER 2). Such targeted testing could involve refinement of the exposure estimation or generation of data from in vitro or in chemico NAMs. Once sufficient information is available, the final stage of the NGRA framework is the determination of a point of departure (POD), characterising uncertainty and comparing to the consumer exposure in a WoE. Thorough evaluation of the sources of uncertainty is essential to ensure transparency and build trust in new risk assessment a